Last $0.0014 USD
Change Today 0.0001 / 7.69%
Volume 29.2M
SVFC On Other Exchanges
As of 3:53 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

intellicell biosciences inc (SVFC) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/13 - $0.02
52 Week Low
08/15/14 - $0.0010
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

intellicell biosciences inc (SVFC) Related Businessweek News

No Related Businessweek News Found

intellicell biosciences inc (SVFC) Details

IntelliCell BioSciences, Inc. operates as a regenerative medicine company in the United States. It develops and commercializes regenerative medicine using adult autologous stromal vascular fraction cells derived from the blood vessels in adipose tissue. The company’s products are intended to treat various clinical conditions, such as aesthetic conditions, orthopedic and sports injuries, and pain, as well as cardiac, gastrointestinal, periodontal, and autistic disorders. It also focuses on undertaking clinical studies in partnership with universities and hospitals for osteoarthritis, gum regeneration, non-healing diabetic ulcers, multiple sclerosis, cartilage regeneration, tendon repair, facial lines and wrinkles, chronic migraine headache, bone regeneration, and hair regeneration indications. In addition, the company is involved in sourcing, selling, and distributing laboratory equipment and supplies, which are used in tissue processing activities. It also licenses its products in Canada, Australia, New Zealand, and Thailand. The company is based in New York, New York.

intellicell biosciences inc (SVFC) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2013.

intellicell biosciences inc (SVFC) Key Developments

IntelliCell BioSciences Appoints Raymond Hill to Board of Directors

IntelliCell BioSciences, Inc. announced that it has added Mr. Raymond Hill to its Board of Directors. Mr. Hill has held a number of senior executive roles in the pharmaceutical industry, including President of InVentiv Clinical, CEO and member of the Board of Directors of PPD, and President of IMS Consulting Group. Earlier on in his career, Mr. Hill was a partner at A.T. Kearney and a consultant at Booz Allen & Hamilton.

IntelliCell BioSciences, Inc. Announces Executive Appointments

IntelliCell BioSciences, Inc. announced that it has added Mr. Vincent S. Dugan as Director of National Sales and Mr. John Huber III as interim Chief Financial Officer. The focus being to strengthen the launch of the establishment of additional cellular labs, all being cGTP, FDA registered labs, in hospitals and ambulatory surgical centers across the country. Mr. Vincent S. Dugan has worked for the past eleven years in the sales of Orthopedic Medical Devices. Mr. John Huber III is a managing partner at Mango & Huber CPAs. His firm's experience with financial reporting and accounting controls will enable IntelliCell BioSciences, Inc. to manage the increased activity stemming from the placement of additional labs using the patented technology.

IntelliCell BioSciences, Inc. announced delayed 10-Q filing

On 08/14/2014, IntelliCell BioSciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVFC:US $0.00 USD 0.0001

SVFC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.30 USD 0.00
Mesoblast Ltd A$4.26 AUD +0.05
Pacific Biosciences of California Inc $5.21 USD +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation SVFC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 56.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELLICELL BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at